Search research articles
Contact Us
Filters
Showing results (251-260 of 265) with videos related to
Page
of 27
Sort By:
Leukemia & Lymphoma
|
December 18, 2015
Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium
Ariela Noy, Shelly Y Lensing, Page C Moore, et al.
Cancer
|
November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
Lakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
Regulatory Toxicology and Pharmacology : RTP
|
July 15, 2025
Corrigendum to "Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics" [Regul. Toxicol. Pharmacol., (161) (2025) 105855]
Anna Engstrom, Tine Dahlbaek Hannibal, Jerome Egli, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 21, 2025
Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics
Anna Engstrom, Tine Dahlbaek Hannibal, Jerome Egli, et al.
BMJ Open
|
October 18, 2023
UK robotic arthroplasty clinical and cost effectiveness randomised controlled trial for hips (RACER-Hip): a study protocol
James Griffin, Edward T Davis, Helen Parsons, et al.
The Journal of Rheumatology
|
September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concerns
Lee S Simon, C Vibeke Strand, Maarten Boers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
JCO Precision Oncology
|
October 5, 2020
Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay
Katherine Clifton, Thereasa A Rich, Christine Parseghian, et al.
Optics Express
|
October 17, 2014
First on-sky SCAO validation of full LQG control with vibration mitigation on the CANARY pathfinder
Gaetano Sivo, Caroline Kulcsár, Jean-Marc Conan, et al.
BMJ (Clinical Research Ed.)
|
June 19, 2004
Grading quality of evidence and strength of recommendations
David Atkins, Dana Best, Peter A Briss, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 265) with videos related to
Sort By:
Page
of 27
Leukemia & Lymphoma
|
December 18, 2015
Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium
Ariela Noy, Shelly Y Lensing, Page C Moore, et al.
Cancer
|
November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
Lakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
Regulatory Toxicology and Pharmacology : RTP
|
July 15, 2025
Corrigendum to "Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics" [Regul. Toxicol. Pharmacol., (161) (2025) 105855]
Anna Engstrom, Tine Dahlbaek Hannibal, Jerome Egli, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 21, 2025
Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics
Anna Engstrom, Tine Dahlbaek Hannibal, Jerome Egli, et al.
BMJ Open
|
October 18, 2023
UK robotic arthroplasty clinical and cost effectiveness randomised controlled trial for hips (RACER-Hip): a study protocol
James Griffin, Edward T Davis, Helen Parsons, et al.
The Journal of Rheumatology
|
September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concerns
Lee S Simon, C Vibeke Strand, Maarten Boers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
JCO Precision Oncology
|
October 5, 2020
Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay
Katherine Clifton, Thereasa A Rich, Christine Parseghian, et al.
Optics Express
|
October 17, 2014
First on-sky SCAO validation of full LQG control with vibration mitigation on the CANARY pathfinder
Gaetano Sivo, Caroline Kulcsár, Jean-Marc Conan, et al.
BMJ (Clinical Research Ed.)
|
June 19, 2004
Grading quality of evidence and strength of recommendations
David Atkins, Dana Best, Peter A Briss, et al.
Page
of 27